DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Suvorexant
Suvorexant
4 Tier)
Orexin Receptor Antagonists As Therapeutic Agents for Insomnia
OREXIN ANTAGONISTS BELSOMRA (Suvorexant), DAYVIGO (Lemborexant)
Merck & Co., Inc
Role of the Orexin Receptor System in Stress, Sleep and Cocaine Use
G Protein-Coupled Receptors
G Protein‐Coupled Receptors
IJBCP International Journal of Basic & Clinical Pharmacology Orexin
Sfn2015 Items of Interest
Persistent Effects of the Orexin-1 Receptor Antagonist SB-334867 on Motivation for the Fast Acting Opioid Remifentanil
Suvorexant Spent in Bed
Belsomra®: a Novel Dual Orexin Receptor Antagonist for the Treatment of Insomnia
United Mine Workers of America Health and Retirement Funds 2021
Lemborexant for Insomnia
The Involvement of the Neuropeptides Orexins (Hypocretins) In
Balanced Drug List Dispensing Limits
Exploring New Frontiers for the Pharmacological Treatment of Insomnia
BELSOMRA® Suvorexant Tablets
Top View
ACNP 59Th Annual Meeting: Poster Session III
G Protein‐Coupled Receptors
Distinct Effects of Orexin Receptor Antagonist and GABAA Agonist on Sleep and Physical/Cognitive Functions After Forced Awakening
New Drugs 2015
Welldynerx 2021 Universal Formulary List
Blue Cross and Blue Shield October 2019 Multi-Tier Basic Drug List I How to Use This List Generic Drugs Are Shown in Lower-Case Boldface Type
Lemborexant (Dayvigo®) FDA Approved December 2019 (Eisai Inc); Schedule IV Controlled Substance
Suvorexant, an Orexin/Hypocretin Receptor Antagonist, Attenuates Motivational and Hedonic Properties of Cocaine
Hypocretin Receptor Antagonists for Insomnia: Rationale and Clinical Data
Efficacy and Safety of Suvorexant for the Treatment of Primary Insomnia Among Chinese
G Protein-Coupled Receptors Product Listing | Edition 1
Characterisation of the Kinetics of Binding of Almorexant and Suvorexant at the Orexin-2 Receptor
FEP 5 Tier Rx Drug Formulary (607) Standard Option
Suvorexant for Sleep-Onset Insomnia Or Sleep-Maintenance Insomnia, Or Both
Current and Emerging Therapies for Insomnia Mei T
Dual'' Orexin Receptor Antagonists at OX1R and OX2R Orexin Receptors
Preferred Drug List (PDL)
Kinetic Properties of "Dual'' Orexin Receptor Antagonists at OX1R And
MAT for Alcohol Use Disorder
The Dual Orexin/Hypocretin Receptor Antagonist Suvorexant Reduces Addiction-Like Behaviors for the Opioid Fentanyl
BELSOMRA Safely and Effectively
MHDL Update B
Clinical Focus (2021) the Phone Number Printed on Your Member ID Card
The Effect of Intracerebroventricular Administration of Orexin Receptor
Repurposing the Dual Orexin Receptor Antagonist Suvorexant for the Treatment of Opioid Use Disorder: Why Sleep on This Any Longer?
Clinical Experience with a Dual Orexin Receptor Antagonist, Suvorexant (Belsomra) in Japan
A Novel Orexin Antagonist from a Natural Plant Was Discovered Using Zebrafish Behavioural Analysis
Formulary Drug Reviews Suvorexant
Targeting the Orexin System for Prescription Opioid Use Disorder
A Novel Dual Orexin Receptor Antagonist S
1 MEDICATION GUIDE BELSOMRA ® (Bell-SOM-Rah)
G Protein-Coupled Receptors
Suvorexant (Belsomra) for Insomnia ANDREA R
The Use of Physiology-Based PK and PD Modeling in the Discovery of the Dual
Effects of Suvorexant, a Dual Orexin/Hypocretin Receptor Antagonist, on Impulsive Behavior Associated with Cocaine
Monday Scienti Ic Session Listings 269–451 Information at a Glance
BELSOMRA Safely and Effectively
Express Scripts Canada Prescription Drug Trend Report Trends in Canadian Private Drug Spend
The Selective Orexin-2 Antagonist Seltorexant (JNJ-42847922/MIN
Identification and Characterization of Cannabidiol As an OX1R
Distinct Effects of IPSU and Suvorexant on Mouse Sleep Architecture
Suvorexant Drug Monograph INFORMATION
Other Review(S)
Structure-Based Development of a Subtype-Selective Orexin 1 Receptor Antagonist
Orexin/Hypocretin Based Pharmacotherapies for the Treatment of Addiction: DORA Or SORA? CNS Drugs, 28, 713-730